Cooperative gene mutations in the 32 AML patients with WT1 mutations*
UPNs . | Class 1 mutations . | Class 2 mutations . | NPM1 mutation . | |||||
---|---|---|---|---|---|---|---|---|
FLT3/ITD . | FLT3/TKD . | NRAS . | KRAS . | RUNX1 . | CEBPA . | MLL/PTD . | ||
1, 9, 19, 24 | + | — | — | — | — | — | — | — |
16, 28 | + | — | — | — | — | — | — | + |
21 | + | — | + | — | — | — | — | + |
26 | + | — | + | — | — | — | — | — |
31 | + | — | — | — | — | — | + | — |
25 | — | + | — | — | + | — | — | — |
23 | — | + | — | — | — | — | — | + |
18 | — | — | — | + | — | — | — | — |
3 | — | — | — | + | — | — | — | — |
2, 5, 11, 15, 22, 30, 32 | — | — | — | — | — | + | — | — |
17 | — | — | — | — | + | — | — | — |
29 | — | — | — | — | — | — | + | — |
4 | — | — | — | — | — | — | — | + |
UPNs . | Class 1 mutations . | Class 2 mutations . | NPM1 mutation . | |||||
---|---|---|---|---|---|---|---|---|
FLT3/ITD . | FLT3/TKD . | NRAS . | KRAS . | RUNX1 . | CEBPA . | MLL/PTD . | ||
1, 9, 19, 24 | + | — | — | — | — | — | — | — |
16, 28 | + | — | — | — | — | — | — | + |
21 | + | — | + | — | — | — | — | + |
26 | + | — | + | — | — | — | — | — |
31 | + | — | — | — | — | — | + | — |
25 | — | + | — | — | + | — | — | — |
23 | — | + | — | — | — | — | — | + |
18 | — | — | — | + | — | — | — | — |
3 | — | — | — | + | — | — | — | — |
2, 5, 11, 15, 22, 30, 32 | — | — | — | — | — | + | — | — |
17 | — | — | — | — | + | — | — | — |
29 | — | — | — | — | — | — | + | — |
4 | — | — | — | — | — | — | — | + |
A total of 23 of the 32 WT1-mutated patients concurrently had other gene mutations, including 13 (56.5%) with class 1 mutations and 16 (69.6%) with class 2 mutations or NPM1 mutations. None of these patients had KIT, PTPN11, or JAK2 mutation.
UPN indicates unique patient number; and —, negative (not mutated).